HK1257100A1 - 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法 - Google Patents

使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法

Info

Publication number
HK1257100A1
HK1257100A1 HK18116351.9A HK18116351A HK1257100A1 HK 1257100 A1 HK1257100 A1 HK 1257100A1 HK 18116351 A HK18116351 A HK 18116351A HK 1257100 A1 HK1257100 A1 HK 1257100A1
Authority
HK
Hong Kong
Prior art keywords
composition
methods
organic compounds
small organic
protein activity
Prior art date
Application number
HK18116351.9A
Other languages
English (en)
Inventor
Thomas E Barta
Jonathan William Bourne
Kyle D Monroe
Michael M Muehlemann
Anjali Pandey
Simeon Bowers
Original Assignee
Portola Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portola Pharm Inc filed Critical Portola Pharm Inc
Publication of HK1257100A1 publication Critical patent/HK1257100A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
HK18116351.9A 2015-08-21 2018-12-20 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法 HK1257100A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208054P 2015-08-21 2015-08-21
US201662298852P 2016-02-23 2016-02-23
PCT/US2016/047810 WO2017034994A1 (en) 2015-08-21 2016-08-19 Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity

Publications (1)

Publication Number Publication Date
HK1257100A1 true HK1257100A1 (zh) 2019-10-11

Family

ID=58101008

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18116351.9A HK1257100A1 (zh) 2015-08-21 2018-12-20 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法

Country Status (4)

Country Link
US (2) US10821106B2 (zh)
EP (1) EP3337497B1 (zh)
HK (1) HK1257100A1 (zh)
WO (1) WO2017034994A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
EP3337788A4 (en) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE
CN105214087B (zh) 2015-10-29 2017-12-26 陈敏 Pcsk9单克隆抗体在制备治疗炎症免疫性疾病药物中的应用
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US769101A (en) * 1903-12-30 1904-08-30 Melvin Mitchell Attachment for grain-drills.
YU163075A (en) 1975-07-21 1982-05-31 Science Union & Cie Process for preparing new phenoxy derivatives
JP2969359B2 (ja) 1989-01-13 1999-11-02 武田薬品工業株式会社 環状アミン化合物
IE912760A1 (en) 1990-08-06 1992-02-12 Smith Kline French Lab Compounds
DK0641320T3 (da) 1991-04-17 2001-08-20 Upjohn Co Substituerede (S)-3-phenylpiperidinderivater, deres fremstilling og deres anvendelse som dopaminautoreceptorantagonister
US5236934A (en) 1992-08-26 1993-08-17 E. I. Du Pont De Nemours And Company 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders
JPH11501281A (ja) * 1993-06-18 1999-02-02 ユニバーシティ オブ シンシナティ 神経ペプチドｙアンタゴニスト及びアゴニスト
US5863903A (en) 1994-03-09 1999-01-26 Novo Nordisk A/S Use of hydroxy alkyl piperidine and pyrrolidine compounds to treat diabetes
CA2187257A1 (en) 1995-10-12 1997-04-13 Enrique Luis Michelotti Aryl-substituted cycloalkanes and cycloalkenes and herbicidal use thereof
US5977134A (en) 1996-12-05 1999-11-02 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
BR9810991A (pt) 1997-07-11 2000-08-08 Smithkline Beecham Plc Novos compostos
US6381025B1 (en) 1999-08-19 2002-04-30 Texas Tech University Interferometric detection system and method
EP1295873A4 (en) 2000-06-14 2004-05-19 METHODS OF PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
WO2003072558A2 (en) 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Arylsulfone derivatives
US20040082641A1 (en) 2002-10-28 2004-04-29 Rytved Klaus Asger Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases
WO2004043929A1 (en) 2002-11-12 2004-05-27 Pfizer Products Inc. Quinoline derivatives
SE0300010D0 (sv) 2003-01-07 2003-01-07 Astrazeneca Ab Novel Compounds
US20040192728A1 (en) 2003-02-03 2004-09-30 Ellen Codd Quinoline-derived amide modulators of vanilloid VR1 receptor
US20060293298A1 (en) 2003-04-10 2006-12-28 Bamford Mark J Compounds
WO2005000309A2 (en) 2003-06-27 2005-01-06 Ionix Pharmaceuticals Limited Chemical compounds
US7268232B2 (en) 2004-05-17 2007-09-11 Acadia Pharmaceuticals Inc. Androgen receptor modulators and method of treating disease using the same
WO2006049597A1 (en) * 2004-10-27 2006-05-11 Avanir Pharmaceuticals Amino acid-derived compounds as modulators of the reverse cholesterol transport
CA2613236A1 (en) 2005-06-30 2007-01-11 Prosidion Limited G-protein coupled receptor agonists
GB0514812D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
AU2006333522A1 (en) 2005-12-21 2007-07-12 Decode Genetics, Ehf. Biaryl nitrogen heterocycle inhibitors of LTA4H for treating inflammation
US20090042857A1 (en) 2006-02-20 2009-02-12 Masuo Yamaoka Novel Pharmaceutical
US7834178B2 (en) 2006-03-01 2010-11-16 Bristol-Myers Squibb Company Triazine 11-beta hydroxysteroid dehydrogenase type 1 inhibitors
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
EP2170866B1 (en) 2007-06-25 2014-08-13 Amgen Inc. Phthalazine compounds, compositions and methods of use
US8445217B2 (en) 2007-09-20 2013-05-21 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
WO2009076372A2 (en) 2007-12-10 2009-06-18 Molecular Sensing, Inc. Temperature-stable interferometer
US8673850B2 (en) 2008-05-30 2014-03-18 Institut De Recherches Cliniques De Montreal PCSK9 inhibitors and methods of use thereof
US8324385B2 (en) 2008-10-30 2012-12-04 Madrigal Pharmaceuticals, Inc. Diacylglycerol acyltransferase inhibitors
EP2483266B1 (en) 2009-10-01 2015-02-25 Cadila Healthcare Limited Compounds for the treatment of dyslipidemia and related diseases
WO2012039660A1 (en) 2010-09-20 2012-03-29 A. Carlsson Research Ab Phenylpiperidine compounds for the treatment of neurological and psychiatric disorders
JP5934787B2 (ja) 2011-05-10 2016-06-15 ギリアード サイエンシーズ， インコーポレイテッド イオンチャネルモジュレーターとしての縮合複素環式化合物
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US20150057949A1 (en) 2012-04-19 2015-02-26 Molecular Sensing, Inc. Event Detection For Back-Scattering Interferometry
AU2013266087A1 (en) 2012-05-25 2014-12-04 Catabasis Pharmaceuticals, Inc. Methods of lowering proprotein convertase subtilisin/kexin type 9 (PCSK9)
WO2014002105A1 (en) 2012-06-25 2014-01-03 Cadila Healthcare Limited Compounds for the treatment of dyslipidemia and other diseases
WO2014101120A1 (en) 2012-12-28 2014-07-03 Merck Sharp & Dohme Corp. Heterobicyclo-substituted-7-methoxy-[1,2,4]triazolo[1,5-c]quinazolin-5-amine compounds with a2a antagonist properties
US10287317B2 (en) 2013-02-15 2019-05-14 Srx Cardio, Llc Proprotein convertase subtilisin kexin type 9 (PCSK9) allosteric binding ligands to modulate serum low density lipoprotein (LDL) levels
JP2016508722A (ja) 2013-02-15 2016-03-24 エスアールエックス カーディオ，エル エル シー 血清低密度リポタンパク質（ｌｄｌ）レベルを調節するためのｐｃｓｋ９（プロタンパク質転換酵素サブチリシン／ケキシン９型）アロステリック結合リガンド
ES2489815B1 (es) 2013-02-21 2015-08-10 Centro De Investigación Príncipe Felipe Nuevos p-terfenilos hexakis-sustituidos con grupos bilaterales para el tratamiento de la infección por el virus de la inmunodeficiencia humana tipo 1 (VIH-1) y otras enfermedades
CN105473141A (zh) 2013-03-15 2016-04-06 实发生物医学公司 治疗和/或预防心血管疾病的抗pcsk9化合物和方法
WO2014150983A2 (en) * 2013-03-15 2014-09-25 Amgen Inc. Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9
WO2015024016A2 (en) 2013-08-16 2015-02-19 Duke University 2-piperidinyl substituted n,3-dihydroxybutanamides
WO2015058129A1 (en) 2013-10-17 2015-04-23 Blueprint Medicines Corporation Compositions useful for treating disorders related to kit
US10034892B2 (en) 2014-08-21 2018-07-31 Srx Cardio, Llc Composition and methods of use of small molecules as binding ligands for the modulation of proprotein convertase subtilisin/kexin type 9(PCSK9) protein activity
US20170267689A1 (en) 2014-08-25 2017-09-21 The Governors Of The University Of Alberta Stimuli-switchable moieties, monomers and polymers incorporating stimuli-switchable moieties, and methods of making and using same
WO2016107602A1 (zh) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 一类取代氮杂环衍生物及其应用
WO2016107603A1 (zh) 2015-01-01 2016-07-07 成都贝斯凯瑞生物科技有限公司 取代氮杂环衍生物及其应用
WO2017034990A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of tetrahydroisoquinoline small molecules to bind and modulate pcsk9 protein activity
WO2017034994A1 (en) 2015-08-21 2017-03-02 Portola Pharmaceuticals, Inc. Composition and methods of use of novel phenylalanine small organic compounds to directly modulate pcsk9 protein activity
EP3337788A4 (en) 2015-08-21 2019-03-27 Portola Pharmaceuticals, Inc. PHENYLPIPERAZINE PROPROTEIN CONVERTASE SUBTILISIN / -KEXIN TYPE 9 P (CSK9) MODULATORS AND THEIR USE
DK3386511T3 (da) 2015-12-10 2021-07-05 Ptc Therapeutics Inc Fremgangsmåder til behandling af huntingtons sygdom
US20190119236A1 (en) 2016-02-23 2019-04-25 Portola Pharmaceuticals, Inc. Compounds for binding proprotein convertase subtilisin/kexin type 9 (pcsk9)
WO2018026866A1 (en) * 2016-08-03 2018-02-08 Neuropore Therapies, Inc. Lipid-substituted amino 1,2-and 1,3-diol compounds as modulators of tlr2 dimerization
EP3609882B1 (en) 2017-03-17 2022-07-13 Cardio Therapeutics Pty Ltd Heterocyclic inhibitors of pcsk9
AU2020291468A1 (en) 2019-06-14 2022-01-06 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9)
US20220193058A1 (en) 2020-12-16 2022-06-23 Srx Cardio, Llc Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (pcsk9)

Also Published As

Publication number Publication date
WO2017034994A1 (en) 2017-03-02
EP3337497A1 (en) 2018-06-27
EP3337497B1 (en) 2023-07-12
US20180237381A1 (en) 2018-08-23
US20210236481A1 (en) 2021-08-05
US10821106B2 (en) 2020-11-03
EP3337497A4 (en) 2019-04-17
US11944619B2 (en) 2024-04-02

Similar Documents

Publication Publication Date Title
HK1257100A1 (zh) 使用新型苯丙胺酸小分子有機化合物來直接調節pcsk9的蛋白活性的組合物和方法
IL267090A (en) Amine-disubstituted heterocyclic compounds as ehmt2 inhibitors and methods of using them
EP3268006A4 (en) Pyrrolotriazine inhibitors of irak4 activity
EP3080100A4 (en) Inhibitors of lysine specific demethylase-1
HK1211471A1 (zh) 通過抑制含布羅莫結構域蛋白 治療 介導的疾病
CL2015000261A1 (es) Alimento para peces de piscifactoría y método para promover el crecimiento de peces de piscifactoría usando el mismo.
EP3558303A4 (en) AMINO ACID COMPOUNDS AND METHOD FOR USE
HK1213471A1 (zh) 作為蛋白脫乙酰基酶抑制劑的嘧啶羥基酰胺化合物及其使用方法
HK1222864A1 (zh) 的小分子調節劑和其使用方法
EP3407916A4 (en) PHOSPHONATE LINKERS AND THEIR USE TO FACILITATE THE CELLULAR RETENTION OF COMPOUNDS
IL251111B (en) An antibody capable of neutralizing a substance with alternative activity to coagulation factor viii (fviii)
EP3142652A4 (en) Heterocyclic hydroxamic acids as protein deacetylase inhibitors and dual protein deacetylase-protein kinase inhibitors and methods of use thereof
EP3228626A4 (en) Peptide having activity to improve skin condition and use thereof
EP2968244A4 (en) COMPOSITIONS AND METHODS FOR USING ALIGAL COMPOUNDS
HK1260897A1 (zh) 使用四氫異喹啉小分子來結合並調節pcsk9的蛋白活性的組合物和方法
EP3313865A4 (en) SYNTHETIC PEPTIDE COMPOUNDS AND METHODS OF USE
EP3191116A4 (en) METHODS OF IDENTIFYING MODULATORS OF SESTRIN-GATOR2 INTERACTION AND USE OF SAME TO MODULATE mTORC1
EP3092244A4 (en) Dipeptides as inhibitors of human immunoproteasomes
EP3219324A4 (en) Application of dipeptide as ace enzyme activity inhibitor
EP3198038A4 (en) Compositions and methods to modulate cell activity
IL248567A0 (en) Using compounds known as d-amino acid oxidase inhibitors
EP3445170A4 (en) CHINOLINE COMPOUNDS AS RAGE ACTIVITY MODULATORS AND USES THEREOF
EP3193904A4 (en) Dipeptidomimetics as inhibitors of human immunoproteasomes
EP3036219A4 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof
EP2994461A4 (en) Methods of treating skin conditions using cyclolignan compounds